LGT Fund Management’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.52M Hold
14,277
0.23% 102
2026
Q1
$4.18M Sell
14,277
-787
-5% -$259K 0.18% 118
2025
Q4
$5.25M Hold
15,064
0.42% 58
2025
Q3
$5.01M Buy
15,064
+3,664
+32% +$1.14M 0.41% 55
2025
Q2
$4.43M Hold
11,400
0.39% 61
2025
Q1
$4.96M Buy
11,400
+6,700
+143% +$2.69M 0.45% 59
2024
Q4
$1.73M Sell
4,700
-4,006
-46% -$1.68M 0.15% 137
2024
Q3
$4.4M Sell
8,706
-275
-3% -$147K 0.46% 60
2024
Q2
$4.87M Buy
8,981
+3,057
+52% +$1.62M 0.61% 49
2024
Q1
$3.07M Sell
5,924
-1,816
-23% -$903K 1.28% 28
2023
Q4
$3.63M Buy
7,740
+120
+2% +$55.5K 1.56% 15
2023
Q3
$3.35M Sell
7,620
-1,990
-21% -$903K 1.63% 13
2023
Q2
$4.27M Sell
9,610
-870
-8% -$401K 1.96% 10
2023
Q1
$4.82M Hold
10,480
2.05% 8
2022
Q4
$5.38M Buy
10,480
+30
+0.3% +$15.2K 2.32% 9
2022
Q3
$4.75M Buy
10,450
+2,700
+35% +$1.29M 2.23% 9
2022
Q2
$3.74M Buy
7,750
+3,000
+63% +$1.48M 0.55% 47
2022
Q1
$2.37M Buy
4,750
+3,300
+228% +$1.51M 0.32% 88
2021
Q4
$672K Buy
+1,450
New +$610K 0.19% 79

Other funds holding ELV

LGT Fund Management's ELV Position: Q2 2026 in Review

LGT Fund Management held its Elevance Health (ELV) position steady in Q2 2026 at 14,277 shares worth $5.52M. The position accounts for 0.23% of the portfolio, ranked #102.

LGT Fund Management first reported a position in ELV in Q4 2021 and has held it in 19 quarters since. 1,602 funds tracked by Wall St. Rank hold ELV as of Q2 2026.

  • LGT Fund Management held 14,277 shares of Elevance Health worth $5.52M as of Q2 2026.
  • LGT Fund Management left its Elevance Health share count unchanged in Q2 2026.
  • Elevance Health made up 0.23% of LGT Fund Management's portfolio in Q2 2026, its #102 holding.
  • LGT Fund Management first reported a position in Elevance Health in Q4 2021 and has held it in 19 quarters since.
  • 1,602 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.

Based on LGT Fund Management's 13F filing for Q2 2026, filed 10 Aug 2026.